Suppr超能文献

雾化布地奈德(普米克令舒)与丙酸倍氯米松(必可酮气雾剂)的体外比较

In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomethasone dipropionate (Clenil per Aerosol).

作者信息

Vaghi A, Berg E, Liljedahl S, Svensson J O

机构信息

Azienda Ospedaliera "G. Salvini", Garbagnate, Italy.

出版信息

Pulm Pharmacol Ther. 2005;18(2):151-3. doi: 10.1016/j.pupt.2004.10.004. Epub 2004 Dec 20.

Abstract

This study compared the in vitro performance of two inhaled corticosteroid products for nebulisation, Pulmicort Respules(budesonide 0.5 mg/mL) and Clenil) per Aerosol (beclomethasone dipropionate (BDP) 0.4 mg/mL). Each product was used in combination with three different nebulisers (2 mL/test, 5 min run time) and the dose to the lungs was determined according to standard methods. The shape of the suspended particles in each product was studied using scanning electron microscopy (SEM). Overall, a higher fine particle dose was achieved with Pulmicort Respules versus Clenil per Aerosol, with estimated dose to the lungs of 8-14 and 3-6% of nominal dose, respectively. SEM showed that budesonide particles were small, typically approximately 2-3 microm in diameter, whereas those of BDP were needle-shaped and up to approximately 10 microm long. The more favourable particle shape and size of suspended budesonide may explain the higher fine particle dose with Pulmicort Respules versus Clenil per Aerosol.

摘要

本研究比较了两种用于雾化吸入的糖皮质激素产品的体外性能,即普米克令舒(布地奈德0.5mg/mL)和气雾剂必可酮(二丙酸倍氯米松(BDP)0.4mg/mL)。每种产品均与三种不同的雾化器联合使用(每次测试2mL,运行时间5分钟),并根据标准方法确定肺部剂量。使用扫描电子显微镜(SEM)研究每种产品中悬浮颗粒的形状。总体而言,与必可酮气雾剂相比,普米克令舒的细颗粒剂量更高,估计肺部剂量分别为标称剂量的8 - 14%和3 - 6%。扫描电子显微镜显示,布地奈德颗粒较小,直径通常约为2 - 3微米,而BDP颗粒呈针状,长度可达约10微米。悬浮的布地奈德更有利的颗粒形状和尺寸可能解释了与必可酮气雾剂相比,普米克令舒的细颗粒剂量更高的原因。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验